Launched by The Max Foundation, Max Access Solutions (MAS) program is an operational program through which humanitarian donations of approved oncology products are channelled to patients in need. The Max Access Solutions program aims to bridge the gaps in access to treatment specifically in countries where the burden of disease is high and local government access programs may not be currently feasible.

The MAS Iclusig® (ponatinib) program is especially critical to CML patients for whom other treatments have proven ineffective and for those who have T315I-positive CML or Ph+ ALL. Through this program, Takeda donates Iclusig® (ponatinib), effective for the treatment of refractory chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), to The Max Foundation to help cancer patients in low- and middle-income countries (LMICs), who would otherwise lack access to the drug due to unavailability in local markets. The Max Foundation provides access to Takeda’s Iclusig® (ponatinib) product to patients in need through their treating physicians. Healthcare providers (HCP) in LMICs initiate the product request and manage the treatment of patients receiving the product from The Max Foundation.

The Foundation works through a third-party logistics provider (3PL) who, as its agent, receives the product from manufacturers and ships it to end users on the organization’s behalf. This ensures the fastest possible time between the drug being prescribed, and is administered to the patient. Takeda in collaboration with the Foundation support partner physicians on the use of the treatment, as well as to providing wrap-around support in areas such as diagnostics and adherence support.